July 18th 2025
Take a look back through some of the top stories from the first half of the year.
GU Tumor Board: Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies
September 27, 2025
Register Now!
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
View More
Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment
View More
Aquablation preserves antegrade ejaculation in men with large prostate glands
October 5th 2021“The majority of treatments out there don't allow the maintenance of ejaculation after surgery, whereas here, we're at 90% for the small glands…[and at] 81% [for] the men who had prostates above 80 grams,” says Naeem Bhojani, MD, FRCSC.
Researchers evaluate data on priapism malpractice litigation
July 30th 2021“I think it's the responsibility of the physician to really take on educating and counseling and setting clear expectations and that way, when complications do arise, patients are better equipped, and they have a more favorable outcome,” says Ariana Matz, MD.
Dr. Ranjith Ramasamy discusses research evaluating COVID-19 and erectile dysfunction
May 19th 2021“I think doctors should be aware that if men do complain of erectile dysfunction after [having] COVID-19 that it could be because of underlying endothelial dysfunction and underlying vasculature issues,” Ramasamy says.
Research suggests potential gaps in ED care delivered by nonurologists
October 16th 2020Men who receive care for erectile dysfunction from their primary care provider are much less likely to receive advanced pharmacological therapies for management of their condition than those treated by urologists.
Sexual dysfunction: Protocol decreases opioid requirements in IPP patients
July 20th 2018The AUA 2018 sexual dysfunction take-home messages also included a novel end-to-side nerve grafting procedure for men with post-radical-prostatectomy ED as well as the finding that use of a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor does not appear to change the adverse effect profile of flibanserin (Addyi).
AUA ’18: Experts pick this year’s key research
May 8th 2018To help you sift the enormous scientific program and prioritize your schedule at the AUA annual meeting, the editors have called upon Urology Times’ editorial advisory board to identify the key research across multiple areas of the specialty.